Belite Bio Future Growth

Future criteria checks 5/6

Belite Bio is forecast to grow earnings and revenue by 65.5% and 69.8% per annum respectively while EPS is expected to grow by 64.9% per annum.

Key information

65.5%

Earnings growth rate

64.9%

EPS growth rate

Pharmaceuticals earnings growth23.5%
Revenue growth rate69.8%
Future return on equityn/a
Analyst coverage

Low

Last updated12 Sep 2024

Recent future growth updates

Recent updates

We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Sep 26
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow

Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

Jul 03
Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?

We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

Mar 20
We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely

An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Jan 10
An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued

Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

Jul 31
Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

May 03
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate

Oct 03

Belite Bio receives approval of begin LBS-008 phase 3 trial in China

Sep 16

Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.

Aug 22

Belite Bio GAAP EPS of -$0.23 beats by $0.05

Aug 12

Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Aug 01
Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans

Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment

Jul 19

Earnings and Revenue Growth Forecasts

NasdaqCM:BLTE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202637-17-5N/A3
12/31/202510-30-36N/A5
12/31/2024N/A-35N/AN/A5
6/30/2024N/A-35N/AN/AN/A
3/31/2024N/A-33N/AN/AN/A
12/31/2023N/A-32-30-30N/A
9/30/2023N/A-31N/AN/AN/A
6/30/2023N/A-23N/AN/AN/A
3/31/2023N/A-18N/AN/AN/A
12/31/2022N/A-13-12-11N/A
9/30/2022N/A-8N/AN/AN/A
6/30/2022N/A-8N/AN/AN/A
3/31/2022N/A-8N/AN/AN/A
12/31/2021N/A-10-8-7N/A
9/30/2021N/A-9N/AN/AN/A
6/30/2021N/A-8-7-7N/A
3/31/2021N/A-7-6-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLTE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.5%).

Earnings vs Market: BLTE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BLTE is expected to become profitable in the next 3 years.

Revenue vs Market: BLTE's revenue (69.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: BLTE's revenue (69.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BLTE's Return on Equity is forecast to be high in 3 years time


Discover growth companies